Lenvatinib, a multikinase inhibitor of VEGF receptors and other receptor tyrosine kinases, plus pembrolizumab showed promising clinical activity in advanced gastric cancer patients (ORR, 69%) [115]. Here, NTRK1 is linked to gastric cancer.